Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Prevalence of genotypic resistance among antiretroviral drug-naive HTV-1-infected patients in Belgium
Autore:
Van Vaerenbergh, K; Debaisieux, L; De Cabooter, N; Declercq, C; Desmet, K; Fransen, K; Maes, B; Marissens, D; Miller, K; Muyldermans, G; Sprecher, S; Stuyver, L; Vaira, D; Verhofstede, C; Zissis, G; Van Ranst, M; De Clercq, E; Desmyter, J; Vandamme, AM;
Indirizzi:
Katholieke Univ Leuven, Rega Inst Med Res, Louvain, Belgium Katholieke Univ Leuven Louvain Belgium a Inst Med Res, Louvain, Belgium Free Univ Brussels, Hop Erasme, B-1070 Brussels, Belgium Free Univ Brussels Brussels Belgium B-1070 sme, B-1070 Brussels, Belgium State Univ Ghent, B-9000 Ghent, Belgium State Univ Ghent Ghent Belgium B-9000 Univ Ghent, B-9000 Ghent, Belgium Inst Trop Med, B-2000 Antwerp, Belgium Inst Trop Med Antwerp Belgium B-2000 t Trop Med, B-2000 Antwerp, Belgium Hop St Pierre, Brussels, Belgium Hop St Pierre Brussels BelgiumHop St Pierre, Brussels, Belgium Inst Pasteur, Brussels, Belgium Inst Pasteur Brussels BelgiumInst Pasteur, Brussels, Belgium Free Univ Brussels, Akad Ziekenhuis, B-1090 Brussels, Belgium Free Univ Brussels Brussels Belgium B-1090 uis, B-1090 Brussels, Belgium Univ Liege, Ctr Hosp, Liege, Belgium Univ Liege Liege BelgiumUniv Liege, Ctr Hosp, Liege, Belgium Innogenetics, Ghent, Belgium Innogenetics Ghent BelgiumInnogenetics, Ghent, Belgium
Titolo Testata:
ANTIVIRAL THERAPY
fascicolo: 1, volume: 6, anno: 2001,
pagine: 63 - 70
SICI:
1359-6535(200103)6:1<63:POGRAA>2.0.ZU;2-P
Fonte:
ISI
Lingua:
ENG
Soggetto:
IMMUNODEFICIENCY-VIRUS TYPE-1; REVERSE-TRANSCRIPTASE; PROTEASE INHIBITORS; HIV-1 VARIANTS; ZIDOVUDINE RESISTANCE; NUCLEOSIDE ANALOG; THERAPY; MUTATIONS; GENE; LAMIVUDINE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
36
Recensione:
Indirizzi per estratti:
Indirizzo: Vandamme, AM Katholieke Univ Leuven, Rega Inst Med Res, Louvain, Belgium Katholieke Univ Leuven Louvain Belgium s, Louvain, Belgium
Citazione:
K. Van Vaerenbergh et al., "Prevalence of genotypic resistance among antiretroviral drug-naive HTV-1-infected patients in Belgium", ANTIVIR TH, 6(1), 2001, pp. 63-70

Abstract

Objectives: To estimate the prevalence and the evolution over time (1995-1998) of genotypic resistance to antiviral drugs in antiretroviral drug-naive HIV-1-infected patients in Belgium. Design: Belgian Aids Reference Laboratories provided retrospective samplesand clinical data from antiretroviral drug-naive HIV-l-infected patients who visited the hospital for the first time in 1995 (n=45), 1997 (n=75) and 1998 (n=111). Genotypic resistance to the three available classes of drugs was monitored using the Line Probe Assay (Innogenetics, Gent, Belgium). Additionally, ARMS-151 was performed for scoring multinucleoside resistance. Results: The prevalence of genotypic resistance at baseline to nucleoside analogue reverse transcriptase inhibitors (NRTls) and non-nucleoside reverse transcriptase inhibitors (NNRTls) were each between 10% and 20% for 1995,1997 and 1998 without an increasing trend over time. For NRTls, resistancemutations were mainly related to zidovudine in 1995, whereas in 1997 and 1998 baseline resistance was scored for zidovudine, lamivudine or for both drugs simultaneously. No patients displayed the multi-nucleoside resistance Q151M mutation. Baseline resistance mutations to protease inhibitors (Pls) did not rise significantly: 4.4% in 1995, 8% in 1997 and 9.9% in 1998. Whenscoring any resistance-related mutation, 26.6% displayed genotypic baseline resistance in 1995, 26.6% in 1997 and 31.5% in 1998. Discussion: The prevalence of genotypic baseline resistance to any drug, as scored with LiPA, in naiveHIV-1 patients in Belgium is 29%, with baselineresistance mutations to one or several drugs from all available classes ofantiviral drugs. The ability of LiPA to pick up minor variants could be anexplanation for the higher overall prevalence we observe, when compared torecent estimates in other countries of 16.3% and 22%, which were based on sequencing methods. According to the European guidelines for resistance testing, resistance testing in Belgium before starting antiviral therapy should be considered.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 06/04/20 alle ore 01:52:51